KL and acute kidney injury: With this background in mind, we review recent progress in the field of NAD+, focusing on: AKI and aging-related biomarkers, including mitochondrial dysfunction, impaired autophagy, reduced level of the kidney biomarker Klotho, and occurrence of renal fibrosis and senescence cells; the progression to CKD; and NAD+ as a potential pharmacological option.